Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
Authors:
- Ben TranBTBen Tran
- Richard D. CarvajalRichard D. Carvajal
- Aurelien MarabelleAMAurelien Marabelle
- Sandip Pravin PatelSPSandip Pravin Patel
- Patricia M. LoRussoPLPatricia M. LoRusso
- Erik RasmussenERErik Rasmussen
- Gloria JuanGJGloria Juan
- Vijay V. UpretiVUVijay V. Upreti
- Courtney BeersCBCourtney Beers
- Gataree NgarmchamnanrithGNGataree Ngarmchamnanrith
- Patrick SchöffskiPSPatrick Schöffski
Open Access
- 25 September 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 93
Abstract
Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor−related protein (GITR), in patients with refractory advanced solid tumors. Methods AMG 228 was administered intravenously every 3 weeks (Q3W). Dose escalation was in two stages: single-patient cohorts (3, 9, 30, and 90 mg), followed by “rolling six” design (n = 2–6; 180, 360, 600, 900, and 1200 mg). Primary endpoints included incidence of dose-limiting toxicities (DLTs), AEs, and pharmacokinetics. Additional endpoints were objective response and pharmacodynamic response. Results Thirty patients received AMG 228, which was well tolerated up to the maximum planned dose (1200 mg). No DLTs occurred; the MTD was not reached. The most common treatment-related AEs were fatigue (13%), infusion-related reaction (7%), pyrexia (7%), decreased appetite (7%), and hypophosphatemia (7%). Two patients had binding anti−AMG 228 antibodies (one at baseline); no neutralizing antibodies were detected. AMG 228 exhibited target-mediated drug disposition, and serum exposure was approximately dose proportional at 180–1200 mg and greater than dose proportional at 3–1200 mg. Doses > 360 mg Q3W achieved serum trough coverage for 95% in vitro GITR occupancy. Despite GITR coverage in peripheral blood and tumor biopsies, there was no evidence of T-cell activation or anti-tumor activity. Conclusions In patients with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200 mg), exhibited favorable pharmacokinetics, and provided target coverage indicating a pharmacokinetic profile appropriate for longer intervals. However, there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy. Trial registration ClinicalTrials.gov, NCT02437916.Keywords
Funding Information
- Amgen Inc.
This publication has 22 references indexed in Scilit:
- Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory CellsCancer Research, 2017
- Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor ImmunotherapyCancer Research, 2017
- Rationale for anti-GITR cancer immunotherapyEuropean Journal of Cancer, 2016
- Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapyCancer Immunology, Immunotherapy, 2010
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six DesignJournal of Clinical Oncology, 2008
- Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+regulatory T cellsJournal of Experimental Medicine, 2005
- Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cellsProceedings of the National Academy of Sciences, 2003
- Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its LigandJournal of Biological Chemistry, 1999
- Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITRCurrent Biology, 1999